

Pharmacovigilance as a Tool for Promoting Safer Medicines and Better Public Health

Kirtimaya Mishra¹, Naresh Kumar Sahoo¹, Laxman Kumar Das¹, Jnyana Ranjan Pradhan¹, Rohit Kumar Singh¹, Diptimayee Jena^{1*}

^{1,1*} School of Pharmacy & Life Sciences, Centurion University of Technology & Management, Bhubaneswar, Odisha

Date of Submission: 25-10-2025

Date of Acceptance: 05-11-2025

ABSTRACT: Pharmacovigilance, which regularly assesses the quality, safety, and effectiveness of medications throughout their life cycle, is essential to protecting the public's health. The prompt identification, evaluation, and prevention of adverse drug reactions (ADRs) have become essential for reducing patient risks due to the increasing complexity of therapeutic approaches and worldwide patterns of medication usage. Pharmacovigilance supports clinical practice, directs patient education, and builds confidence in healthcare systems in addition to bolstering regulatory decision-making. Pharmacovigilance supports the early detection of safety signals and the encouragement of responsible drug use by combining empirical data, sophisticated data analytics, and efficient reporting mechanisms. This improves treatment results, lays the groundwork for safer medications, and eventually advances public health objectives. To handle present and future drug safety issues, pharmacovigilance frameworks must be strengthened by global cooperation, digital tools, and active stakeholder involvement. Pharmacovigilance is therefore an essential tool for striking a balance between pharmaceutical innovation and human health protection.

KEYWORDS: Quality, Safety, Effectiveness, Adverse Drug Reactions, Therapeutic Approaches, Clinical practice, Patient Education, Regulatory Decision-Making.

I. INTRODUCTION:

¹⁻³Vigilare is a Latin term that means "to keep watch," "awake, attentive," "being vigilant in relation to risk, care, precaution, and cautiousness," and "the act of exhibiting constant, undisturbed attentiveness." Pharmakon means "drug" in Greek, and it is the analysis and methods for recognizing, assessing, understanding, and avoiding adverse effects or other possible drug-related problems. These days, biologicals, medical equipment, blood products, conventional and alternative medications,

herbs, and vaccinations are among its wider interests. Pharmacovigilance, according to reports, is crucial for making sure that the patient and doctor are knowledgeable about a particular treatment and helping them select the right medication. It's harder than ever to maximize drug safety while preserving public confidence. From product discovery to post-market, pharmaceutical and biotechnology companies need to continuously evaluate and control medication risk.

⁴⁻¹⁰To optimize benefits and reduce risks, pharmacological effects, adverse reactions, restrictions, and obviously harmful outcomes that could result in a high degree of disease and, in certain situations, deaths must be carefully monitored. Because clinical studies might include hundreds of individuals, less common adverse drug reactions (ADRs) and side effects are often unknown until a product is presented to the market. Pharma regulatory authorities must have a strong PV system in place to track adverse drug reactions (ADRs) both throughout the medication development phase and later on during the usage of a licensed medicine. Post-marketing PV utilizes methods such as data mining and case report analysis to ascertain the relationships between drugs and adverse drug reactions (ADRs).

¹¹⁻¹⁵There was no real need for a robust PV system to identify adverse drug reactions (ADRs) of marketed pharmaceuticals because so few novel medications have been identified in India and even fewer first debuted there. Companies and regulatory agencies assessed the safety criteria and put corrective measures in place, such the medication's withdrawal or limitation, using the knowledge they had gathered from markets where the drug had been used for years before it was released in India. The pharmaceutical and biotechnology industries have adopted an innovative patent regulation known as TRIPS, or Trade Related Intellectual Property Rights and Services, which requires India to refrain from

copying trademarked products and publicizing them despite the innovator company's consent. After recognizing the demands of the new government, major Indian companies have already begun to invest a sizeable sum of money in the research and development of new medications that are needed for both the Indian and international markets. Pre-clinical and clinical data generated primarily in India suggest that Indian pharmaceutical and biotech companies should conduct study and development to create new medications in the future year.

HISTORICAL CONTEXT:

¹⁶⁻²³On January 29, 1848, a young girl from northern England named Hannah Greener passed away following the removal of an infectious toenail under chloroform anesthesia, marking the beginning of pharmacovigilance 169 years ago. Sir James Simpson used chloroform in clinical settings after discovering it was a safer and more effective anesthetic. Hannah's reason for death was never determined, despite the fact that everything that occurred surrounding her death were investigated in order to discover more about what happened to her. She most likely died from a deadly arrhythmia or from breathing in her lungs. The US Federal Food and Drug Act, originally went into effect on June 30, 1906, mandated that medications be entirely unadulterated and pure. In 1911, this committee also outlawed the use of fictitious medicinal claims for medications. In the United States, 107 people died in 1937 as a result of consuming sulfanilamide elixir, that includes diethyl glycol as a solvent. This solvent was believed to be the primary cause of death at the time, despite the producing companies' ignorance of its harmful consequences. In 1938, the US Federal Food, Drug, and Cosmetic Act was established to modernize the public health sector. The new strategy states that before pharmaceuticals are authorized for sale and factory investigations are permitted, their security should be proven. In 1938, Douthwaite suggested that acetylsalicylic acid (ASA) might be a cause of melena. The results of the study on the gastrointestinal toxicity of ASA were mixed. However, since it was shown in 1955 that ASA can result in gastrointestinal issues, it is currently illegal for usage in patients who have stomach ulcers.

NEED OF PHARMACOVIGILANCE:

²⁴⁻²⁷An efficient pharmacovigilance system is more crucial than ever for guaranteeing the safe use of pharmaceuticals. There are many reasons for

this expansion. Preclinical safety data is lack of dependability. The results of clinical studies largely determine experiences with regards to safety and potency concerns when a medication is initially made available. Determining potency, side effects, and the overall risk-benefit ratio in a particular therapeutic setting takes a lot of time because clinical trials are usually carried out in carefully monitored environments. The majority of research conducted during the drug development process focused on evaluating the effectiveness of pharmaceuticals. Even while the negative effects are also noted, they are not highly applicable to daily life. Preclinical drug research involves testing the safety and effectiveness of drugs in animal trials, and extrapolating results from these studies to humans is usually impractical. Clinical studies involving human subjects are frequently carried out with a small sample size (sometimes more than 3,000) and under closely watched circumstances. The data collected is private and well-selected. Professional trials usually don't involve specific groups like children, the elderly, or expectant mothers, nor are they carried out in environments characteristic of professional practice. Because of this, it is difficult to forecast the frequency of adverse pharmacological effects in the particular population and in certain circumstances, such as when other medications are used concurrently or when medical problems are present.

COMPONENTS OF PHARMACOVIGILANCE:

²⁸⁻³²To ensure continued drug safety throughout a medicine's lifecycle, pharmacovigilance consists of the following components:

- ❖ Data collection
- ❖ Signal detection
- ❖ Risk assessment
- ❖ Risk management strategies
- ❖ Communication
- ❖ Regulatory compliance
- ❖ International collaboration.

The identification, reporting, evaluation, and prevention of adverse drug reactions (ADRs) and other drug-related problems are also included in pharmacovigilance.

REGULATORY FRAMEWORK:

³³⁻³⁵According to the knowledge available at the time, a new medicine is approved if its benefits and hazards are satisfactorily balanced. New information will be produced soon after an invention is introduced, which could affect the

product's benefit-risk analysis. To guarantee the safe use of all pharmaceuticals, a thorough analysis of the new data produced by pharmacovigilance programs is necessary. When a product is recommended and used by large numbers of people in settings different from the clinical trials, nothing less than preventive measures during the pre-clinical and clinical investigation phases can ensure complete safety.

A pharmaceutical company with a commercial license in India is required under Schedule Y to ensure that it has an adequate pharmacovigilance system in in order to ensure that it takes care of its commercialized pharmaceuticals. Each pharmaceutical business with a marketing license must fulfill its pharmacovigilance responsibilities when two or more marketed drugs

are similar save for their trade names. This involves setting up and keeping up a suitable pharmacovigilance system to gather, compile, and assess data regarding possible adverse events. DCGI must be informed of any adverse reaction reports as well as details regarding a product's benefit-risk analysis. A pharmaceutical company can accomplish this by either establishing internal pharmacovigilance systems or by entering into agreements with CROs that specialize in pharmacovigilance functions to fulfill their pharmacovigilance responsibilities.

REPORTING OF ADRS:

Reporting of ADRs will be done after collecting the data. The flowchart of Reporting is illustrated in Fig 1.




Fig 1: Flowchart of Reporting

AI IN PHARMACOVIGILANCE:

³⁶⁻³⁹The range of medical information that is already available has grown significantly over the past few years and is predicted to continue to do so in the near future due to the extensive marketing of digital tools that collect personally identifiable data. There is a chance to enhance drug safety

assessment by applying artificial intelligence (AI) methods to the analysis of vast volumes of digital information. In clinical research, information retrievalthe process of extracting pertinent concepts from readily available, primarily unstructured sources utilizing text mining and natural language processing (NLP) techniques—has become

increasingly significant. Study participants and medical professionals can monitor pharmaceutical safety in terms of pharmacovigilance by using text analysis and natural language processing (NLP) technologies to collect data on adverse drug reactions (ADRs) and drug-drug interactions from a variety of textual sources. In fact, both governmental and private organizations are working to create artificial intelligence (AI) systems that will enable autonomous processing of ADRs.

Pharmacovigilance may also benefit from AI and machine learning in the following ways:

- ❖ The automated execution of tasks related to case report entry and processing
- ❖ Finding groups of adverse occurrences that point to signs of a syndrome
- ❖ Doing studies in pharmacoepidemiology
- ❖ Linking data using probabilistic matching inside datasets
- ❖ The application of certain models developed from real data to forecast and prevent adverse events.

FUTURE PROSPECTIVE OF PHARMACOVIGILANCE:

Because of expanded pharmaceutical drug research, more stringent regulations, and the use of cutting-edge technologies including computational intelligence and machine learning, the field of pharmacovigilance will have a wide range of uses in the future. Real-world data, personalized medicine, and ecopharmacovigilance are some of the new approaches to drug safety monitoring that are driving up need for qualified individuals with regulatory, analytical, and teamwork skills.

II. CONCLUSION:

Given the increasing number of clinical investigations and other investigative operations now being conducted in India, it is imperative to understand the importance of pharmacovigilance and its impact on a medication's life cycle. In order to guarantee regulatory compliance while enhancing the safety of clinical trials and post-marketing monitoring which will help in evaluating the potential hazards, advantages, and adverse effects of pharmaceuticals and promote their cautious, secure and more efficient use-this will enable the integration of effective pharmacovigilance methods into protocols. In addition, this will enhance pharmacovigilance education, training, and expertise as well as its

efficient dissemination to the general public and healthcare providers.

REFERENCE:

- [1]. Phillips, K. A., Veenstra, D. L., Oren, E. (2001). Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. *Journal of the American Medical Association*, 4, 2270-2279.
- [2]. Shuka, S. S., Gidwani, B., Pandey, R., Rao, S. P., Singh, V., et al. (2012). Importance of Pharmacovigilance in Indian Pharmaceutical Industry. *Asian Journal of Research in Pharmaceutical Sciences*, 2, 4-8.
- [3]. Norwood, P. K., Sampson, A. R. (1988). A statistical methodology for postmarketing surveillance of adverse drug reaction reports. *Stat Med*, 7, 1023-1030.
- [4]. Aneesh, T. P., Sonal, S. M., Jose, A., Chandran, L., Zachariah, S. M. (2009). Pharmacogenomics: The Right Drug to the Right Person. *Journal of Clinical Medicine Research*, 1, 191-194.
- [5]. Whitebread, S., Hamon, J., Bojanic, D., Urban, L. (2005). Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. *Drug Discovery Today*, 10, 1421-1433.
- [6]. Lazarou, J., Pomeranz, B. H., Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *Journal of the American Medical Association*, 279, 1200-1205.
- [7]. Lopes, P., Nunes, T., Campos, D., Furlong, L. I., Bauer-Mehren, A., et al. (2013). Gathering and Exploring Scientific Knowledge in Pharmacovigilance. *PLoS ONE*, 8(12), e83016.
- [8]. Meyboom, R. H. B., Lindquist M., Egberts, A. C. G., Edwards, I. R. (2002). Signal Selection and Follow-Up in Pharmacovigilance. *Drug Safety*, 25, 459-465.
- [9]. Robb, M. A., Racoosin, J. A., Sherman, R. E., Gross, T. P., Ball, R., et al. (2012). The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety. *Pharmacoepidemiology Drug Safety*, 21, 9-11.

- [10]. Härmark, L., van Grootheest, A. C. (2008). Pharmacovigilance: methods, recent developments and future perspectives. *European Journal of Clinical Pharmacology*, 64, 743-752.
- [11]. Jeeya, A., Mishra, K., Jena, D., Prasanth, D., Jabeen, A., Sahoo, S., Bhatta, P. (2023). An overview of Prosopis Juliflora's pharmacologic aspects. *International Journal of Pharmacognosy & Life Science*, 4(1), 121-126.
- [12]. Lindquist, M. (2008). VigiBase; the WHO Global ICSR Database System: Basic Facts. *Drug Information Journal*, 42, 409-419.
- [13]. Tripathy, R., Basha, S., Jain, R., Shetty, S., Ramachandran, A. (2008). Exenatide and acute pancreatitis. *Journal of the Association of Physicians of India*, 56, 987-988.
- [14]. Kumar, S., Baldi, A. (2013). Pharmacovigilance in India: Perspectives and Prospects. *Journal of Drug Delivery & Therapeutics*, 3, 237-246.
- [15]. Routledge, P. (1998). 150 years of pharmacovigilance. *Lancet*, 351, 1200-1201.
- [16]. Fornasier, G., Francescon, S., Leone, R., Baldo, P. (2018). An historical overview over Pharmacovigilance. *International Journal of Clinical Pharmacy*, 40(4), 744-747.
- [17]. FDA ConsumerMagzine. <https://www.fda.gov/downloads/AboutFDA/WhatWeDo/History/Origin/ucm125604.doc> (1981). Accessed 28 Oct 2025
- [18]. Woolf, A. D. (1998). The Haitian diethylene glycol poisoning tragedy: a dark wood revisited. *Journal of the American Medical Association*, 279, 1215-1216.
- [19]. Islam, A., Jena, D., Mondal, N. S., Teli, A., Mondal, S. (2025). In-silico approaches for drug designing technology: Bridging discovery and development. *Current Drug Discovery Technologies*, 22(5), e15701638326869.
- [20]. Food and Drug Administration (FDA). History. <https://www.fda.gov/AboutFDA/WhatWeDo/History/>. Accessed 28 Oct 2025.
- [21]. Douthwaite, A. H. (1938). Some recent advances in medical diagnosis and treatment. *British Medical Journal*. 1, 1143.
- [22]. Kumar, S., Baldi, A. (2013). Pharmacovigilance in India: Perspectives and Prospects. *Journal of Drug Delivery & Therapeutics*, 3, 237-246.
- [23]. Deepa, A. (2008). Pharmacovigilance obligations of the pharmaceutical companies in India. *Indian Journal of Pharmacology*, 40, S13-S16.
- [24]. Gautam, M. K., Jena, D., Jabeen, A., Mukherjee, R., Buralla, K. K., Mishra, K. (2023). Using Green Chemistry Concepts in Developing and Validating Analytical Methods for Meropenem in Parenteral Dosage Form: A Quality by Design Point of View. *Journal of Chemical Health Risks*, 13(6), 189-196.
- [25]. Grady, C. (2005). Payment of clinical research subjects. *Journal of Clinical Investigation*, 115, 1681-1687.
- [26]. Brahmachari, B., Fernandes, M., Bhatt, A. (2011). Pharmacovigilance for clinical trials in India: Current practice and areas for reform. *Perspectives in Clinical Research*, 2, 49-53.
- [27]. Biswas, P., Biswas, A. K. (2007). Setting standards for proactive pharmacovigilance in India. *Indian Journal of Pharmacology*. 39, 124-128.
- [28]. Don, M. (2006). Safety reporting during clinical trials: the new amended regulations in India. *Pipeline*, 9, 4-7.
- [29]. Mishra, K., Padmasri, B., Vegesna, S., Jabeen, A., Dash, A., Kumar, S., Jena, D. (2023). Chemometric Assisted UV-Spectrophotometric Quantification of Cefaclor in Suspension Dosage Form. *International Journal of Pharmaceutical Quality Assurance*, 14(3), 734-739.
- [30]. Adithan, C. (2005). National Pharmacovigilance Programme. *Indian Journal of Pharmacology*, 37, 347.
- [31]. Kulkarni, R. D. (1986). Reporting system for rare side effects of non-narcotic analgesics in India: problems and opportunities. *Medical Toxicology*, 1, 110-113.
- [32]. Ahmad, A., (2012). Pharmacovigilance: Areas To Reform. *Indo American Journal of Pharm Research*, 2(9), 1002-1010.
- [33]. Giezen, T. J. (2009). Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at

- time of regulatory approval. *Drug Safety*, 32, 1175-1187.
- [34]. Martirosyan, L. A. (2010). Systematic literature review: Prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. *Pharmacoepidemiology Drug Safety*, 19, 319-334.
- [35]. Sundhararajan, R., Sabarisenhil, Ahamed, S. N., Rilvan, M. F., Sathish, B., Sathish, K.R., Shakeel, A. H., **Jena, D. (2023).** GC-MS Analysis of Chemical Substances from Ethanolic Extract of *Prosopis juliflora* Leaves. *The Journal of Phytopharmacology*; 12(4), 253-257.
- [36]. Wong, A., Plasek, J. M., Montecalvo, S. P., Zhou, L. (2018). Natural Language Processing and its Implications for the Future of Medication Safety: A Narrative Review of Recent Advances and Challenges. *Pharmacotherapy*, 38(8), 822-841.
- [37]. Crisafulli, S., Ientile, V., Labbate, L., Fontana, A., Linguiti, C., Manna, S., et al. (2021). COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. *Journal of clinical medicine*, 11(1), 51.
- [38]. Holm, G., Snape, J. R., Murray-Smith, R., Talbot, J., Taylor, D., Sörme, P. (2013). Implementing Ecopharmacovigilance in Practice: Challenges and Potential Opportunities. *Drug Safety*, 36(7), 533-546.
- [39]. Niburski, K., Niburski, O. (2020). Impact of Trump's Promotion of Unproven COVID-19 Treatments on Social Media and Subsequent Internet Trends: Observational Study. *Journal of Medical Internet Research*, 22(11), e20044.